New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
10:36 EDTAZN, MDT, ABT, PFE, AGN, MYL, COV, VRXTreasury calls on Congress to halt inversion deals
Congress should "shut down" tax inversion deals, Treasury Secretary Jack Lew wrote in a letter to key members of Congress. Tax inversion deals have been embraced in recent months by a number of drug companies looking to lower their tax bills. WHAT'S NEW: In a letter to leaders of Congressional committees that deal with tax legislation, Lew said legislation to shut down tax inversion deal should be enacted immediately and made retroactive to May 2014. The Obama administration seeks to take comprehensive action to reform and simplify the U.S. tax system, but as it works to do that Congress should crack down on this loophole, Lew said. BACKGROUND: Tax inversions refer to an acquisition of one company, usually officially based in a country in Europe or elsewhere, by a U.S. company, following which the acquiring company becomes domiciled in the same country as the company that it bought. The switch has the potential to significantly lower the acquiring company's tax rate. ANALYST REACTION: In a note to investors earlier today, BMO Capital analyst David Maris wrote that anti-inversion rhetoric from the Obama administration may cause the environment for inversion deals to become "quite chilly." Although Congress is unlikely to act on this issue soon, the risk of legislation could make some companies think twice about paying high premiums for competitors they are acquiring in inversion deals, the analyst warned. Investors should be especially cautious about deals that are pending or have been recently announced, such as Mylan's (MYL) acquisition of Abbott’s (ABT) established products business announced on Monday, Maris wrote. Lew's letter will also hinder Valeant's (VRX) efforts to acquire Allergan (AGN), as the Treasury Secretary's statement will bolster Allergan's argument that Valeant's tax assumptions could be overly positive, according to the analyst. Maris has Outperform ratings on all the stocks mentioned except for Mylan, on which he has an Underperform rating. Another high-profile proposed deal in the pharmaceutical space that involved a potential inversion was Pfizer's (PFE) failed attempt to acquire AstraZeneca (AZN). Additionally, Medtronic (MDT) recently agreed to acquire Ireland's Covidien (COV). PRICE ACTION: In early trading, Mylan was little changed at $52.20, Abbott was fractionally higher to $41.25, Valeant was little changed at $120, Allergan traded fractionally lower at $164.30, Medtronic fell 1.7% to $62.48 and Covidien dropped 2% to $88.67.
News For MYL;ABT;VRX;AGN;MDT;COV;PFE;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 14, 2015
13:31 EDTMDTMedtronic says Evera MRI ICD study meets safety, efficacy endpoints
Subscribe for More Information
12:29 EDTPFEPfizer receives 'second request' from FTC regarding potential Hospira merger
Subscribe for More Information
09:41 EDTMDT, ABTLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
09:22 EDTAZNLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:39 EDTPFETargacept, Catalyst Biosciences amend definitive merger agreement
Subscribe for More Information
08:08 EDTPFEPfizer director Marc Tessier-Lavigne to step down from board
Subscribe for More Information
05:52 EDTAZNMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
19:17 EDTPFEHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
17:24 EDTAZNAstraZeneca to update progress with immuno-oncology pipeline at ASCO
AstraZeneca and MedImmune, the company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology, or ASCO, Annual Meeting, May 29-June 2. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
17:19 EDTPFEPfizer, Merck KGaA to present data at ASCO for avelumab
Subscribe for More Information
13:43 EDTPFEHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
07:31 EDTPFEHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
10:02 EDTMDTMedtronic receives FDA approval and CE Mark for Advance ST cryoballoon
Subscribe for More Information
May 11, 2015
17:36 EDTPFEAthersys down 10.1% after Pfizer notified that it will terminate agreement
Subscribe for More Information
17:34 EDTPFEAthersys receives notification that Pfizer will terminate agreement
Subscribe for More Information
16:33 EDTPFEPfizer takes minority interest in AM-Pharma, secures option to acquire company
AM-Pharma and Pfizer announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of $87.5M for the minority equity interest and exclusive option, with additional potential payments of up to $512.5M upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed. “Pfizer is committed to advancing the science to address the high unmet medical need in Acute Kidney Injury,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “Clinical data for recAP show the potential to uniquely address Acute Kidney Injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients.”
14:27 EDTMYLCowen recommends adding to both Teva and Mylan at current levels
Cowen recommends adding to both Teva (TEVA) and Mylan (MYL) at current levels. The firm continues to believe that a Mylan transaction will proceed despite some early contentious language, and all of Mylan's concerns will be resolved.
11:53 EDTMYLTeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
10:30 EDTABTAbbott names Brian Yoor as SVP, Finance and CFO
Subscribe for More Information
06:01 EDTMYLStocks with implied volatility movement; MYL NOK
Stocks with implied volatility movement; Mylan (MYL) 43, Nokia (NOK) 34 according to iVolatility.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use